Azelastine Hydrochloride Nasal Spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older.
The recommended dosage of Azelastine Hydrochloride Nasal Spray in adults and adolescent patients 12 years and older with seasonal allergic rhinitis is one or two sprays per nostril twice daily. The recommended dosage of Azelastine Hydrochloride Nasal Spray in pediatric patients 5 years to 11 years of age is one spray per nostril twice daily. The recommended dosage of Azelastine Hydrochloride Nasal Spray in adults ...
Azelastine Hydrochloride Nasal Spray, 0.1% (137 mcg/spray) is supplied as a 30-mL package (NDC 72162-1601-3) delivering 200 metered sprays in a high-density polyethylene (HDPE) bottle fitted with a metered-dose spray pump unit. The spray pump unit consists of a nasal spray pump fitted with a white safety clip and a white plastic dust cover. The net content of the bottle is 30 mL (net weight 30 gm of solution). Eac...
www.fda.gov/medwatch
www.bpirx.comAzelastine Hydrochloride Nasal Spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older.
The recommended dosage of Azelastine Hydrochloride Nasal Spray in adults and adolescent patients 12 years and older with seasonal allergic rhinitis is one or two sprays per nostril twice daily. The recommended dosage of Azelastine Hydrochloride Nasal Spray in pediatric patients 5 years to 11 years of age is one spray per nostril twice daily.
The recommended dosage of Azelastine Hydrochloride Nasal Spray in adults and adolescent patients 12 years and older with vasomotor rhinitis is two sprays per nostril twice daily.
Administer Azelastine Hydrochloride Nasal Spray by the intranasal route only.
Priming: Prime Azelastine Hydrochloride Nasal Spray before initial use by releasing 4 sprays or until a fine mist appears. When Azelastine Hydrochloride Nasal Spray has not been used for 3 or more days, reprime with 2 sprays or until a fine mist appears. Avoid spraying Azelastine Hydrochloride Nasal Spray into the eyes.
Azelastine Hydrochloride Nasal Spray is a nasal spray solution. Each spray of Azelastine Hydrochloride Nasal Spray delivers a volume of 0.137 mL solution containing 137 mcg of azelastine hydrochloride.
None.
In clinical trials, the occurrence of somnolence has been reported in some patients taking Azelastine Hydrochloride Nasal Spray [see Adverse Reactions (6.1) ]. Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness and motor coordination such as operating machinery or driving a motor vehicle after administration of Azelastine Hydrochloride Nasal Spray. Concurrent use of Azelastine Hydrochloride Nasal Spray with alcohol or other central nervous system depressants should be avoided because additional reductions in alertness and additional impairment of central nervous system performance may occur [see Drug Interactions (7.1) ].
Use of Azelastine Hydrochloride Nasal Spray has been associated with somnolence [see Warnings and Precautions (5.1) ].
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in practice.
Seasonal Allergic Rhinitis
Azelastine Hydrochloride Nasal Spray Two Sprays Per Nostril Twice Daily
Adverse experience information for Azelastine Hydrochloride Nasal Spray is derived from six placebo- and active-controlled, 2-day to 8-week clinical trials which included 391 patients, 12 years of age and older, with seasonal allergic rhinitis who received Azelastine Hydrochloride Nasal Spray at a dose of 2 sprays per nostril twice daily. In placebo-controlled efficacy trials, the incidence of discontinuation due to adverse reactions in patients receiving Azelastine Hydrochloride Nasal Spray and vehicle placebo was 2.2% and 2.8%, respectively.
Table 1 contains adverse reactions that were reported with frequencies ≥2% in the Azelastine Hydrochloride Nasal Spray 2 sprays per nostril twice daily treatment group and more frequently than placebo.
| Azelastine Hydrochloride Nasal Spray N = 391 | Vehicle Placebo N = 353 | |
|---|---|---|
| Bitter Taste | 77 (19.7%) | 2 (0.6%) |
| Headache | 58 (14.8%) | 45 (12.7%) |
| Somnolence | 45 (11.5%) | 19 (5.4%) |
| Nasal Burning | 16 (4.1%) | 6 (1.7%) |
| Pharyngitis | 15 (3.8%) | 10 (2.8%) |
| Paroxysmal Sneezing | 12 (3.1%) | 4 (1.1%) |
| Dry Mouth | 11 (2.8%) | 6 (1.7%) |
| Nausea | 11 (2.8%) | 4 (1.1%) |
| Rhinitis | 9 (2.3%) | 5 (1.4%) |
| Fatigue | 9 (2.3%) | 5 (1.4%) |
| Dizziness | 8 (2.0%) | 5 (1.4%) |
| Epistaxis | 8 (2.0%) | 5 (1.4%) |
| Weight Increase | 8 (2.0%) | 0 (0.0%) |
Azelastine Hydrochloride Nasal Spray One Spray Per Nostril Twice Daily
Adverse experience information for Azelastine Hydrochloride Nasal Spray at a dose of one spray per nostril twice daily is derived from two placebo-controlled 2-week clinical studies which included 276 patients 12 years of age and older with seasonal allergic rhinitis. The incidence of discontinuation due to adverse reactions in patients receiving Azelastine Hydrochloride Nasal Spray and vehicle placebo was 0.0% and 0.8%, respectively. Bitter taste was reported in 8.3% of patients compared to none in the placebo group. Somnolence was reported in 0.4% of patients compared to none in the placebo group.
A total of 176 patients 5 to 11 years of age were exposed to Azelastine Hydrochloride Nasal Spray at a dose of 1 spray each nostril twice daily in 3 placebo-controlled studies. In these studies, adverse reactions that occurred more frequently in patients treated with Azelastine Hydrochloride Nasal Spray than with placebo, and that were not represented in the adult adverse reactions table above include rhinitis/cold symptoms (17.0% vs. 9.5%), cough (11.4% vs. 8.3%), conjunctivitis (5.1% vs. 1.8%), and asthma (4.5% vs. 4.1%).
Adverse Reactions <2% in Azelastine Hydrochloride Nasal Spray One or Two Sprays Per Nostril Twice Daily
The following reactions were observed infrequently (<2% and exceeding placebo incidence) in patients who received Azelastine Hydrochloride Nasal Spray dosed at 1 or 2 sprays per nostril twice daily in U.S. clinical trials.
Cardiovascular: flushing, hypertension, tachycardia.
Dermatological: contact dermatitis, eczema, hair and follicle infection, furunculosis, skin laceration.
Digestive: constipation, gastroenteritis, glossitis, ulcerative stomatitis, vomiting, increased SGPT, aphthous stomatitis, diarrhea, toothache.
Metabolic and Nutritional: increased appetite.
Musculoskeletal: myalgia, temporomandibular dislocation, rheumatoid arthritis.
Neurological: hyperkinesia, hypoesthesia, vertigo.
Psychological: anxiety, depersonalization, depression, nervousness, sleep disorder, thinking abnormal.
Respiratory: bronchospasm, coughing, throat burning, laryngitis, bronchitis, dry throat, nocturnal dyspnea, nasopharyngitis, nasal congestion, pharyngolaryngeal pain, sinusitis, nasal dryness, paranasal sinus hypersecretion, post nasal drip.
Special Senses: conjunctivitis, eye abnormality, eye pain, watery eyes, taste loss.
Urogenital: albuminuria, amenorrhea, breast pain, hematuria, increased urinary frequency.
Whole Body: allergic reaction, back pain, herpes simplex, viral infection, malaise, pain in extremities, abdominal pain, pyrexia.
Vasomotor Rhinitis
Adverse experience information for Azelastine Hydrochloride Nasal Spray is derived from two placebo-controlled clinical studies which included 216 patients 12 years and older with vasomotor rhinitis who received Azelastine Hydrochloride Nasal Spray at a dose of 2 sprays per nostril twice daily for up to 28 days. The incidence of discontinuation due to adverse reactions in patients receiving Azelastine Hydrochloride Nasal Spray and vehicle placebo was 2.8% and 2.9%, respectively.
The following adverse reactions were reported with frequencies ≥ 2% in the Azelastine Hydrochloride Nasal Spray treatment group and more frequently than placebo.
| Azelastine Hydrochloride Nasal Spray N = 216 | Vehicle Placebo N = 210 | |
|---|---|---|
| Bitter Taste | 42 (19.4%) | 5 (2.4%) |
| Headache | 17 (7.9%) | 16 (7.6%) |
| Dysesthesia | 17 (7.9%) | 7 (3.3%) |
| Rhinitis | 12 (5.6%) | 5 (2.4%) |
| Epistaxis | 7 (3.2%) | 5 (2.4%) |
| Sinusitis | 7 (3.2%) | 4 (1.9%) |
| Somnolence | 7 (3.2%) | 2 (1.0%) |
Reactions observed infrequently (<2% and exceeding placebo incidence) in patients who received Azelastine Hydrochloride Nasal Spray (2 sprays/nostril twice daily) in U.S. clinical trials in vasomotor rhinitis were similar to those observed in U.S. clinical trials in seasonal allergic rhinitis.
In controlled trials involving nasal and oral azelastine hydrochloride formulations, there were infrequent occurrences of hepatic transaminase elevations.
During the post approval use of Azelastine Hydrochloride Nasal Spray, the following adverse reactions have been identified. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions reported include: anaphylaxis, application site irritation, atrial fibrillation, chest pain, confusion, dyspnea, facial edema, involuntary muscle contractions, nasal sores, palpitations, paresthesia, parosmia, pruritus, rash, disturbance or loss of sense of smell and/or taste, tolerance, urinary retention, vision abnormal and xerophthalmia.
Concurrent use of Azelastine Hydrochloride Nasal Spray with alcohol or other central nervous system depressants should be avoided because reductions in alertness and impairment of central nervous system performance may occur [see Warnings and Precautions (5.1) ].
Risk Summary
Limited data from postmarketing experience over decades of use with Azelastine hydrochloride in pregnant women have not identified any drug associated risks of miscarriage, birth defects, or other adverse maternal or fetal outcomes. In animal reproduction studies, there was no evidence of fetal harm at oral doses approximately 5 times the clinical daily dose. Oral administration of azelastine hydrochloride to pregnant mice, rats, and rabbits, during the period of organogenesis, produced developmental toxicity that included structural abnormalities, decreased embryo-fetal survival, and decreased fetal body weights at doses 270 times and higher than the maximum recommended human daily intranasal dose (MRHDID) of 1.096 mg. However, the relevance of these findings in animals to pregnant women was considered questionable based upon the high animal to human dose multiple.
The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Data
Animal Data
In an embryo-fetal development study in mice dosed during the period of organogenesis, azelastine hydrochloride caused embryo-fetal death, structural abnormalities (cleft palate; short or absent tail; fused, absent or branched ribs), delayed ossification, and decreased fetal weight at approximately 300 times the maximum recommended human daily intranasal dose (MRHDID) in adults (on a mg/m2 basis at a maternal oral dose of 68.6 mg/kg/day), which also caused maternal toxicity as evidenced by decreased maternal body weight. Neither fetal nor maternal effects occurred in mice at approximately 15 times the MRHDID in adults (on a mg/m2 basis at a maternal oral dose of 3 mg/kg/day).
In an embryo-fetal development study in pregnant rats dosed during the period of organogenesis from gestation days 7 to 17, azelastine hydrochloride caused structural abnormalities (oligo-and brachydactylia), delayed ossification, and skeletal variations, in the absence of maternal toxicity, at approximately 270 times the MRHDID in adults (on a mg/m2 basis at a maternal oral dose of 30 mg/kg/day). Azelastine hydrochloride caused embryo-fetal death and decreased fetal weight and severe maternal toxicity at approximately 610 times the MRHDID (on a mg/m2 basis at a maternal oral dose of 68.6 mg/kg/day). Neither fetal nor maternal effects occurred at approximately 20 times the MRHDID (on a mg/m2 basis at a maternal oral dose of 2 mg/kg/day).
In an embryo-fetal development study in pregnant rabbits dosed during the period of organogenesis from gestation days 6 to 18, azelastine hydrochloride caused abortion, delayed ossification and decreased fetal weight and severe maternal toxicity at approximately 530 times the MRHDID in adults (on a mg/m2 basis at a maternal oral dose of 30 mg/kg/day). Neither fetal nor maternal effects occurred at approximately 5 times the MRHDID (on a mg/m2 basis at a maternal oral dose of 0.3 mg/kg/day).
In a prenatal and postnatal development study in pregnant rats dosed from late in the gestation period and through the lactation period from gestation day 17 through lactation day 21, azelastine hydrochloride produced no adverse developmental effects on pups at maternal doses up to approximately 270 times the MRHDID (on mg/m2 basis at a maternal dose of 30 mg/kg/day).
Risk Summary
There are no data on the presence of azelastine hydrochloride in human milk, the effects on the breastfed infant, or the effects on milk production. Breastfed infants should be monitored for signs of milk rejection during Azelastine Hydrochloride Nasal Spray use by lactating women (see Clinical Considerations). The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Azelastine Hydrochloride Nasal Spray and any potential adverse effects on the breastfed infant from Azelastine Hydrochloride Nasal Spray or from the underlying maternal condition.
Clinical Considerations
Monitoring for Adverse Reactions
Breastfed infants of lactating women treated with Azelastine Hydrochloride Nasal Spray should be monitored for possible signs of milk rejection related to the bitter taste of azelastine hydrochloride.
The safety and effectiveness of Azelastine Hydrochloride Nasal Spray for the treatment of symptoms of seasonal allergic rhinitis have been established for patients 5 years and older [see Adverse Reactions (6.1) and Clinical Studies (14.1) ]. The safety and effectiveness of Azelastine Hydrochloride Nasal Spray for the treatment of vasomotor rhinitis have been established for patients 12 years and older [see Adverse Reactions (6.1) and Clinical Studies (14.2) ]. The safety and effectiveness of Azelastine Hydrochloride Nasal Spray in pediatric patients below the age of 5 years with seasonal allergic rhinitis and in pediatric patients below the age of 12 years with vasomotor rhinitis have not been established.
Clinical trials of Azelastine Hydrochloride Nasal Spray did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
There have been no reported overdosages with Azelastine Hydrochloride Nasal Spray. Acute overdosage by adults with this dosage form is unlikely to result in clinically significant adverse reactions, other than increased somnolence, since one bottle of Azelastine Hydrochloride Nasal Spray contains 30 mg of azelastine hydrochloride. Clinical trials in adults with single doses of the oral formulation of azelastine hydrochloride (up to 16 mg) have not resulted in increased incidence of serious adverse reactions. General supportive measures should be employed if overdosage occurs. There is no known antidote to Azelastine Hydrochloride Nasal Spray. Oral ingestion of antihistamines has the potential to cause serious adverse effects in young children. Accordingly, Azelastine Hydrochloride Nasal Spray should be kept out of the reach of children.
Azelastine Hydrochloride Nasal Spray, 0.1% (137 micrograms (mcg) per spray), is an antihistamine formulated as a metered-spray solution for intranasal administration. Azelastine hydrochloride occurs as a white, almost odorless, crystalline powder with a bitter taste. It has a molecular weight of 418.37. It is sparingly soluble in water, methanol, and propylene glycol and slightly soluble in ethanol, octanol, and glycerine. It has a melting point of about 225°C and the pH of a saturated solution is between 5.0 and 5.4. Its chemical name is (±)-1-(2H)-phthalazinone, 4-[(4-chlorophenyl) methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-, monohydrochloride. Its molecular formula is C22H24ClN3O∙HCl with the following chemical structure:
Azelastine Hydrochloride Nasal Spray contains 0.1% azelastine hydrochloride in an aqueous solution at pH 6.8 ± 0.3. It also contains benzalkonium chloride (125 mcg/mL), edetate disodium, hypromellose, citric acid, dibasic sodium phosphate heptahydrate, sodium chloride, and purified water.
After priming [see Dosage and Administration (2.3) ], each metered spray delivers a 0.137 mL mean volume containing 137 mcg of azelastine hydrochloride (equivalent to 125 mcg of azelastine base). The bottle can deliver 200 metered sprays.
Azelastine hydrochloride, a phthalazinone derivative, exhibits histamine H1-receptor antagonist activity in isolated tissues, animal models, and humans. Azelastine Hydrochloride Nasal Spray is administered as a racemic mixture with no difference in pharmacologic activity noted between the enantiomers in in vitro studies. The major metabolite, desmethylazelastine, also possesses H1-receptor antagonist activity.
Cardiac Electrophysiology:
In a placebo-controlled study (95 subjects with allergic rhinitis), there was no evidence of an effect of Azelastine Hydrochloride Nasal Spray (2 sprays per nostril twice daily for 56 days) on cardiac repolarization as represented by the corrected QT interval (QTc) of the electrocardiogram. Following multiple dose oral administration of azelastine 4 mg or 8 mg twice daily, the mean change in QTc was 7.2 msec and 3.6 msec, respectively.
Interaction studies investigating the cardiac repolarization effects of concomitantly administered oral azelastine hydrochloride and erythromycin or ketoconazole were conducted. These drugs had no effect on QTc based on analysis of serial electrocardiograms. At a dose approximately 8 times the maximum recommended dose, azelastine hydrochloride does not prolong the QTc interval to any clinically relevant extent.
Absorption: After intranasal administration, the systemic bioavailability of azelastine hydrochloride is approximately 40%. Maximum plasma concentrations (Cmax) are achieved in 2-3 hours.
Azelastine hydrochloride administered intranasally at doses above two sprays per nostril twice daily for 29 days resulted in greater than proportional increases in Cmax and area under the curve (AUC) for azelastine.
Distribution: Based on intravenous and oral administration, the steady-state volume of distribution is 14.5 L/kg. In vitro studies with human plasma indicate that the plasma protein binding of azelastine and its metabolite, desmethylazelastine, are approximately 88% and 97%, respectively.
Metabolism: Azelastine is oxidatively metabolized to the principal active metabolite, desmethylazelastine, by the cytochrome P450 enzyme system. The specific P450 isoforms responsible for the biotransformation of azelastine have not been identified. After intranasal dosing of azelastine hydrochloride to steady-state, plasma concentrations of desmethylazelastine range from 20-50% of azelastine concentrations. Limited data indicate that the metabolite profile is similar when azelastine hydrochloride is administered via the intranasal or oral route.
Elimination: Based on intravenous and oral administration, the elimination half-life and plasma clearance are 22 hours and 0.5 L/h/kg, respectively. Approximately 75% of an oral dose of radiolabeled azelastine hydrochloride was excreted in the feces with less than 10% as unchanged azelastine.
Special Populations:
Hepatic Impairment: Following oral administration, pharmacokinetic parameters were not influenced by hepatic impairment.
Renal Impairment: Based on oral, single-dose studies, renal insufficiency (creatinine clearance <50 mL/min) resulted in a 70-75% higher Cmax and AUC compared to normal subjects. Time to maximum concentration was unchanged.
Age: Following oral administration, pharmacokinetic parameters were not influenced by age.
Gender: Following oral administration, pharmacokinetic parameters were not influenced by gender.
Race: The effect of race has not been evaluated.
Drug-Drug Interactions:
Erythromycin: No significant pharmacokinetic interaction was observed with the co-administration of orally administered azelastine (4 mg twice daily) with erythromycin (500 mg three times daily for 7 days). In this study, co-administration of orally administered azelastine with erythromycin resulted in Cmax of 5.36 ± 2.6 ng/mL and AUC of 49.7 ± 24 ng∙h/mL for azelastine, whereas, administration of azelastine alone resulted in Cmax of 5.57 ± 2.7 ng/mL and AUC of 48.4 ± 24 ng∙h/mL for azelastine.
Cimetidine and Ranitidine: In a multiple-dose, steady-state drug interaction trial in healthy subjects, cimetidine (400 mg twice daily) increased orally administered mean azelastine (4 mg twice daily) concentrations by approximately 65%. No pharmacokinetic interaction was observed with co-administration of orally administered azelastine (4 mg twice daily) with ranitidine hydrochloride (150 mg twice daily). Oral co-administration of azelastine with ranitidine resulted in Cmax of 8.89 ±3.28 ng/mL and AUC of 88.22 ± 40.43 ng∙h/mL for azelastine, whereas, azelastine when administered alone resulted in Cmax of 7.83 ± 4.06 ng/mL and AUC of 80.09 ± 43.55 ng∙h/mL for azelastine.
Theophylline: No significant pharmacokinetic interaction was observed with the co-administration of an oral 4 mg dose of azelastine hydrochloride twice daily and theophylline 300 mg or 400 mg twice daily.
Two-year carcinogenicity studies in Crl:CD(SD)BR rats and NMRI mice were conducted to assess the carcinogenic potential of azelastine hydrochloride. No evidence of tumorigenicity was observed in rats at doses up to 30 mg/kg day (approximately 270 and 240 times the MRHDID for adults and children, respectively, on a mg/m2 basis). No evidence for tumorigenicity was observed in mice at doses up to 25 mg/kg (approximately 110 and 100 times the MRHDID for adults and children, respectively, on a mg/m2 basis).
Azelastine hydrochloride showed no genotoxic effects in the Ames test, DNA repair test, mouse lymphoma forward mutation assay, mouse micronucleus test, or chromosomal aberration test in rat bone marrow.
There were no effects on male or female fertility and reproductive performance in male and female rats at oral doses up to 30 mg/kg (approximately 270 times the MRHDID in adults on a mg/m2 basis). At 68.6 mg/kg (approximately 610 times the MRHDID on a mg/m2 basis), the duration of estrous cycles was prolonged and copulatory activity and the number of pregnancies were decreased. The numbers of corpora lutea and implantations were decreased; however, pre-implantation loss was not increased.
Two Sprays Per Nostril Twice Daily
The efficacy and safety of Azelastine Hydrochloride Nasal Spray were evaluated in three placebo-controlled clinical trials of Azelastine Hydrochloride Nasal Spray including 322 patients with seasonal allergic rhinitis who received two sprays per nostril twice a day for up to 4 weeks. These trials included 55 pediatric patients ages 12 to 16 years. Assessment of efficacy was based on the 12-hour reflective Total Symptom Complex (TSC) and Major Symptom Complex (MSC). The MSC was calculated as the average of individual symptoms of nose blows, sneezes, runny nose/sniffles, itchy nose, and watery eyes as assessed by patients on a 0-5 categorical scale. Azelastine Hydrochloride Nasal Spray two sprays per nostril twice daily demonstrated a greater decrease in the MSC than placebo (Table 3).
| Treatment | N | Baseline LS Mean (SD) | Change from Baseline (SD) | Treatment Difference | P-value | |
|---|---|---|---|---|---|---|
| Trial 1: 12 Hour AM and PM Reflective MSC | ||||||
| Azelastine Hydrochloride Nasal Spray | 63 | 11.48 (4.13) | -3.05 (3.51) | 1.98 | <0.01 | |
| Placebo Nasal Spray | 60 | 10.84 (4.53) | -1.07 (3.52) | |||
| Trial 2: 12 Hour AM and PM Reflective MSC | ||||||
| Azelastine Hydrochloride Nasal Spray | 63 | 12.50 (4.5) | -4.10 (3.46) | 2.03 | <0.01 | |
| Placebo Nasal Spray | 63 | 12.18 (4.64) | -2.07 (4.01) | |||
| Trial 3: 12 Hour AM and PM Reflective MSC | ||||||
| Azelastine Hydrochloride Nasal Spray | 66 | 12.04 (4.03) | -3.31 (3.74) | 1.35 | 0.04 | |
| Placebo Nasal Spray | 66 | 11.66 (3.96) | -1.96 (3.57) | |||
* Major Symptom Complex (MSC): Average of individual symptoms of nose blows, sneezes, runny nose/sniffles, itchy nose, and watery eyes as assessed by patients on a 0-5 categorical scale.
In dose-ranging trials, administration of Azelastine Hydrochloride Nasal Spray two sprays per nostril twice daily resulted in a statistically significant decrease in symptoms compared to saline placebo within 3 hours after initial dosing and persisted over the 12-hour dosing interval.
One Spray Per Nostril Twice Daily
The efficacy and safety of Azelastine Hydrochloride Nasal Spray were evaluated in two placebo-controlled clinical trials of Azelastine Hydrochloride Nasal Spray including 275 patients with seasonal allergic rhinitis who received one spray per nostril twice a day for up to 2 weeks. Assessment of efficacy was based on the 12-hour reflective Total Nasal Symptom Score [rTNSS]. rTNSS is calculated as the sum of the patients scoring of four individual nasal symptoms (runny nose, sneezing, itchy nose, and nasal congestion) as assessed by patients on a 0-3 categorical scale. The primary efficacy endpoint was the change from Baseline to Day 14 in rTNSS. The mean change from baseline in rTNSS was greater in patients receiving Azelastine Hydrochloride Nasal Spray one spray per nostril twice daily than those receiving placebo (Table 4).
| Treatment | N | Baseline LS Mean (SD) | Change from Baseline (SD) | Treatment Difference | P-value | |
|---|---|---|---|---|---|---|
| Trial 4: 12 Hour AM and PM Reflective TNSS | ||||||
| Azelastine Hydrochloride Nasal Spray | 138 | 16.34 (4.22) | -2.69 (4.79) | 1.38 | 0.01 | |
| Placebo Nasal Spray | 141 | 17.21 (4.32) | -1.31 (4.29) | |||
| Trial 5: 12 Hour AM and PM Reflective TNSS | ||||||
| Azelastine Hydrochloride Nasal Spray | 137 | 16.62 (4.20) | -3.68 (4.16) | 1.18 | 0.02 | |
| Placebo Nasal Spray | 136 | 16.84 (4.77) | -2.50 (4.01) | |||
* Total Nasal Symptom Score (TNSS): Average of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestion as assessed by patients on a 0-3 categorical scale.
Two-week studies comparing the efficacy (and safety) of Azelastine Hydrochloride Nasal Spray two sprays per nostril twice daily versus one spray per nostril twice daily were not conducted.
The efficacy and safety of Azelastine Hydrochloride Nasal Spray were evaluated in two placebo-controlled clinical trials of Azelastine Hydrochloride Nasal Spray including 216 patients with vasomotor rhinitis who received two sprays per nostril twice a day for up to 4 weeks. These patients had vasomotor rhinitis for at least one year, negative skin tests to indoor and outdoor aeroallergens, negative nasal smears for eosinophils, and negative sinus X-rays. Azelastine Hydrochloride Nasal Spray demonstrated a significantly greater decrease in a symptom complex comprised of rhinorrhea, post nasal drip, nasal congestion, and sneezing compared to placebo.
Azelastine Hydrochloride Nasal Spray, 0.1% (137 mcg/spray) is supplied as a 30-mL package (NDC 72162-1601-3) delivering 200 metered sprays in a high-density polyethylene (HDPE) bottle fitted with a metered-dose spray pump unit. The spray pump unit consists of a nasal spray pump fitted with a white safety clip and a white plastic dust cover. The net content of the bottle is 30 mL (net weight 30 gm of solution). Each bottle contains 30 mg (1 mg/mL) of azelastine hydrochloride. After priming [see DOSAGE AND ADMINISTRATION (2.3)], each spray delivers a fine mist containing a mean volume of 0.137 mL solution containing 137 mcg of azelastine hydrochloride. The correct amount of medication in each spray cannot be assured before the initial priming and after 200 sprays have been used, even though the bottle is not completely empty. The bottle should be discarded after 200 sprays have been used. Azelastine Hydrochloride Nasal Spray should not be used after the expiration date "EXP" printed on the medicine label and carton.
Storage:
Store between 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F). [See USP Controlled Room Temperature]. Protect from freezing.
See FDA-approved patient labeling (Patient Information and Instructions for Use).
Activities Requiring Mental Alertness
Somnolence has been reported in some patients taking Azelastine Hydrochloride Nasal Spray. Caution patients against engaging in hazardous occupations requiring complete mental alertness and motor coordination such as driving or operating machinery after administration of Azelastine Hydrochloride Nasal Spray [see Warnings and Precautions (5.1) ].
Concurrent Use of Alcohol and other Central Nervous System Depressants
Instruct patients to avoid concurrent use of Azelastine Hydrochloride Nasal Spray with alcohol or other central nervous system depressants because additional reductions in alertness and additional impairment of central nervous system performance may occur [see Warnings and Precautions (5.1) ].
Common Adverse Reactions
Inform patients that the treatment with Azelastine Hydrochloride Nasal Spray may lead to adverse reactions, which include bitter taste, headache, somnolence, dysesthesia, rhinitis, nasal burning, pharyngitis, epistaxis, sinusitis, paroxysmal sneezing, nausea, dry mouth, fatigue, dizziness, and weight increase [see Adverse Reactions (6.1) ].
Priming
Instruct patients to prime the pump before initial use and when Azelastine Hydrochloride Nasal Spray has not been used for 3 or more days [see Dosage and Administration (2.3) ].
Keep Spray Out of Eyes
Instruct patients to avoid spraying Azelastine Hydrochloride Nasal Spray into their eyes.
Keep Out of Children's Reach
Instruct patients to keep Azelastine Hydrochloride Nasal Spray out of the reach of children. If a child accidentally ingests Azelastine Hydrochloride Nasal Spray, seek medical help or call a poison control center immediately.
Distributed by:
Breckenridge Pharmaceutical, Inc.
Berlin, CT 06037
Manufactured by:
Woodfield Pharmaceutical, LLC
Houston, TX 77099
Azelastine Hydrochloride Nasal Spray
| Important: For use in your nose only. |
What is Azelastine Hydrochloride Nasal Spray?
It is not known if Azelastine Hydrochloride Nasal Spray is safe and effective in children with seasonal allergic rhinitis under 5 years of age or in children with vasomotor rhinitis under 12 years of age.
What should I tell my healthcare provider before using Azelastine Hydrochloride Nasal Spray?
Before using Azelastine Hydrochloride Nasal Spray, tell your healthcare provider if you are:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Azelastine Hydrochloride Nasal Spray and other medicines may affect each other, causing side effects.
How should I use Azelastine Hydrochloride Nasal Spray?
What should I avoid while using Azelastine Hydrochloride Nasal Spray?
Azelastine Hydrochloride Nasal Spray can cause sleepiness:
What are the possible side effects of Azelastine Hydrochloride Nasal Spray?
The most common side effects of Azelastine Hydrochloride Nasal Spray include:
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all of the possible side effects of Azelastine Hydrochloride Nasal Spray. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store Azelastine Hydrochloride Nasal Spray?
Keep Azelastine Hydrochloride Nasal Spray and all medicines out of reach of children.
General information about the safe and effective use of Azelastine Hydrochloride Nasal Spray.
Medicines are sometimes prescribed for conditions other than those listed in a Patient Information leaflet. Do not use Azelastine Hydrochloride Nasal Spray for a condition for which it was not prescribed. Do not give Azelastine Hydrochloride Nasal Spray to other people, even if they have the same symptoms that you have. It may harm them.
This Patient Information leaflet summarizes the most important information about Azelastine Hydrochloride Nasal Spray. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about Azelastine Hydrochloride Nasal Spray that is written for health professionals.
For more information go to www.bpirx.com or call 1-800-367-3395.
What are the ingredients in Azelastine Hydrochloride Nasal Spray?
Active ingredient: azelastine hydrochloride
Inactive ingredients: benzalkonium chloride, edetate disodium, hypromellose, citric acid, dibasic sodium phosphate heptahydrate, sodium chloride, and purified water.
Azelastine Hydrochloride Nasal Spray
| Important: For use in your nose only. |
For the correct dose of medicine:
Figure A identifies the parts of your Azelastine Hydrochloride Nasal Spray pump
 | |
| Figure A |
Before you use Azelastine Hydrochloride Nasal Spray for the first time, you will need to prime the bottle.
Priming your Azelastine Hydrochloride Nasal Spray
Remove the white dust cover over the tip of the pump and the white safety clip just under the "shoulders" of the pump (See Figure B ).
 | |
| Figure B |
Hold the bottle upright with 2 fingers on the shoulders of the spray pump unit and
Now your pump is primed and ready to use.
 | |
| Figure C |
Using your Azelastine Hydrochloride Nasal Spray
Step 1. Blow your nose to clear your nostrils.
Step 2. Keep your head tilted downward toward your toes.
Step 3. Place the spray tip about ¼ inch to ½ inch into 1 nostril. Hold bottle upright and aim the spray tip toward the back of your nose (See Figure D ).
 | |
| Figure D |
Step 4. Close your other nostril with a finger. Press the pump 1 time and sniff gently at the same time, keeping your head tilted forward and down (See Figure E ).
 | |
| Figure E |
Step 5. Repeat Step 3 and Step 4 in your other nostril.
Step 6. If your healthcare provider tells you to use 2 sprays in each nostril, repeat Steps 2 through 4 above for the second spray in each nostril.
Step 7. Breathe in gently, and do not tilt your head back after using Azelastine Hydrochloride Nasal Spray. This will help to keep the medicine from going into your throat.
Step 8. When you finish using your Azelastine Hydrochloride Nasal Spray, wipe the spray tip with a clean tissue or cloth. Put the safety clip and dust cover back on the bottle.
Cleaning the Spray Tip of your Azelastine Hydrochloride Nasal Spray
|
| |
| Figure F | Figure G |
This Patient Information and Instructions for Use has been approved by the U.S. Food and Drug Administration.
Distributed by:
Breckenridge Pharmaceutical, Inc.
Berlin, CT 06037
Manufactured by:
Woodfield Pharmaceutical, LLC
Houston, TX 77099
Revised: 08/2019
Azelastine Hydrochloride 0.1% Spray, #30ml
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 72162-1601-3 | ML - Milliliter | 72162-1601 | 2d6172a5-1cda-4eec-9409-9482fc4a6a4c | 1 | 2024-03-12 |
| 51991-814-03 | ML - Milliliter | 51991-814 | 54ff59c5-9c43-4c71-a634-a91eb0fb4dff | 1 | 2015-09-10 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 72162-1601 | 72162-1601-3 |
| 51991-814 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| AZELASTINE HYDROCHLORIDE | 0L591QR10I | ACTIB |
| BENZALKONIUM CHLORIDE | F5UM2KM3W7 | IACT |
| EDETATE DISODIUM | 7FLD91C86K | IACT |
| HYPROMELLOSE, UNSPECIFIED | 3NXW29V3WO | IACT |
| CITRIC ACID MONOHYDRATE | 2968PHW8QP | IACT |
| SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE | 70WT22SF4B | IACT |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| WATER | 059QF0KO0R | IACT |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A090176-001 | AZELASTINE HYDROCHLORIDE | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | 2015-07-28 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | 2015-07-28 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | 2015-07-28 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | 2015-07-28 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | 2015-07-28 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | 2015-07-28 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | 2015-07-28 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | 2015-07-28 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A090176-001 | AZELASTINE HYDROCHLORIDE | EQ 0.125MG BASE/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A090176-001 | AZELASTINE HYDROCHLORIDE | EQ 0.125MG BASE/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A090176-001 | AZELASTINE HYDROCHLORIDE | EQ 0.125MG BASE/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A090176-001 | AZELASTINE HYDROCHLORIDE | EQ 0.125MG BASE/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A090176-001 | AZELASTINE HYDROCHLORIDE | EQ 0.125MG BASE/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A090176-001 | AZELASTINE HYDROCHLORIDE | EQ 0.125MG BASE/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A090176-001 | AZELASTINE HYDROCHLORIDE | EQ 0.125MG BASE/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A090176-001 | AZELASTINE HYDROCHLORIDE | EQ 0.125MG BASE/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | A090176-001 | AZELASTINE HYDROCHLORIDE | 0.137MG/SPRAY | SPRAY, METERED / NASAL | AB | 2015-07-28 | f41ea6bd6efb… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A090176-001 | AB | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A090176-001 | AB | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A090176-001 | AB | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A090176-001 | AB | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A090176-001 | AB | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A090176-001 | AB | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A090176-001 | AB | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A090176-001 | AB | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A090176-001 | AB | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A090176-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A090176-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A090176-001 | AB | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A090176-001 | AB | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A090176-001 | AB | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A090176-001 | AB | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A090176-001 | AB | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A090176-001 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A090176-001 | AB | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A090176-001 | AB | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A090176-001 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A090176-001 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A090176-001 | AB | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A090176-001 | AB | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A090176-001 | AB | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A090176-001 | AB | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A090176-001 | AB | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A090176-001 | AB | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A090176-001 | AB | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A090176-001 | AB | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A090176-001 | AB | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A090176-001 | AB | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A090176-001 | AB | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A090176-001 | AB | 1 | f41ea6bd6efb… |
| 2022-09-29 23:25 UTC | 2022-09 | A090176-001 | AB | 1 | e64feba35796… |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A090176-001 | AB | 1 | cb3db0bc1861… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| c769a426-78c9-4aca-8b9d-705da13e29ed | d72f2db8-38fa-40b1-ada2-2ecb847328bc | 2024-01-30 | Warnings, Adverse reactions | c769a426-78c9-4aca-8b9d-705da13e29ed d72f2db8-38fa-40b1-ada2-2ecb847328bc |
Adverse event summaries are temporarily unavailable. Other product information remains available.
